SELL and macrophage activation syndrome: However, in SJIA patients with systemically active disease and features of early/subclinical MAS, substantially more hypersegmented cells were visualized, particularly amongst the CD16+CD62Ldim population compared to CD16+CD62L+ cells (22.9% vs. 11.3%; Figures 2C,D).